lian jiang

lian jiang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2021 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
YWYuchun Wang
Yuchun Wang
LJlian jiang
lian jiang

1 January 2020 in Clinics
Verified
Journal Article
Open access
PDF file
YYYiwei Yan
Yiwei Yan
LJlian jiang
lian jiang
MLMei Li
Mei Li
HZHuifen Zhang
Huifen Zhang
YSYing Shen
Ying Shen
WZWenting Zhang
Wenting Zhang
OBJECTIVES: To evaluate the diagnostic value of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), and the MMP-9/TIMP-1 ratio in fetal inflammatory response syndrome (FIRS), and determine a possible association with the incidence of bronchopulmonary dysplasia (BPD) and myocardial injury. METHODS: Overall, 61 cases of preterm infants with FIRS were divided into the FIRS group 1 (≤32 weeks) and FIRS group 2 (32 to 37 weeks). Similarly, 57 cases of normal preterm infants were divided into Control group 1 and [...] OBJECTIVES: To evaluate the diagnostic value of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), and the MMP-9/TIMP-1 ratio in fetal inflammatory response syndrome (FIRS), and determine a possible association with the incidence of bronchopulmonary dysplasia (BPD) and myocardial injury. METHODS: Overall, 61 cases of preterm infants with FIRS were divided into the FIRS group 1 (≤32 weeks) and FIRS group 2 (32 to 37 weeks). Similarly, 57 cases of normal preterm infants were divided into Control group 1 and

1 May 2015 in Immunology Letters
Verified
Journal Article
Closed access
FWFengming Wang
Fengming Wang
LCLei Chen
Lei Chen
QSQiong Shen
Qiong Shen
TLTong Liu
Tong Liu
LJlian jiang
lian jiang
CLCuiping Liu
Cuiping Liu

4 November 2024 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
GHGailing Hao
Gailing Hao
WGWenjin Geng
Wenjin Geng
CLChunzhen Li
Chunzhen Li
QLQuanheng Li
Quanheng Li
NZNan Zhang
Nan Zhang
LJlian jiang
lian jiang
To analyze the critical factors of infection-associated Hemophagocytic lymphohistiocytosis (HLH) in children, so as to provide theoretical basis for clinic

1 December 2010
Verified
Journal Article
Closed access
FQFan Qu
Fan Qu
CZChun-Hua Zhao
Chun-Hua Zhao
YDYu-Qiao Diao
Yu-Qiao Diao
XZXiu-Li Zhu
Xiu-Li Zhu
JCJian Chen
Jian Chen
JJJiang Jin
Jiang Jin

24 October 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
YYYiwei Yan
Yiwei Yan
YHYuanyuan Hou
Yuanyuan Hou
XZXiuli Zhu
Xiuli Zhu
JCJian Chen
Jian Chen
WZWenting Zhang
Wenting Zhang
LJlian jiang
lian jiang
Classic Hodgkin lymphoma (cHL) is a malignant tumor in children. At present, some patients cannot be cured with first-line treatment, and many cured patients die prematurely because of the late toxic effects of treatment. In addition, effective early survival prediction biomarkers are lacking. The aim of this study was to explore the predictive value of B-cell linker protein (BLNK) in cHL. Sixty-three patients from the Fourth Hospital of Hebei Medical University were included in the study from January 2008 to March 2024 (training set). Immunohistochemistry was used to measure the expression of BLNK. Eleven patients with < 10% BLNK-positive cells (BLNK-negative, BLNK-) and 52 patients with 10 ~ 49% BLNK-positive cells (BLNK-positive, BLNK+) were included. The correlations between BLNK expression and clinicopathological features were analyzed. Univariate and multivariate Cox analyses were used to determine the independent prognostic variables of overall survival (OS) and progression-free survival (PFS). Construction and validation of nomogram to predict PFS of cHL patients. In addition, we included 29 patients with cHL who were admitted between January 2000 and December 2007 as a validation set to explore the robustness of the above prediction model. The OS and PFS of cHL patients in the BLNK+ group were significantly longer than those of patients in the BLNK- group. BLNK expression, the presence of bulky disease, the B lymphocyte count, LDH levels and the neutrophil count were determined to be independent prognostic factors by multivariable Cox regression analysis of PFS. A nomogram model was constructed based on these factors. The discriminative ability of the nomogram was good; the C-index was 0.844 (0.761, 0.926) in the training set and 0.824 (0.717, 0.931) in the validation set. The results of the calibration curve suggested strong agreement between the forecast and actual observations in both the training set and the validation set. Subgroup analysis successfully identified a treatment-sensitive population of cHL patients to predict prognosis according to the BLNK level. In the subgroups without giant tumor lesions, an age≥9 years, St. Jude Stages III–IV, chemotherapy regimens (1/2), a CRP concentration >7.5 mg/L, a B lymphocyte count >5.7 × 10^6/L, a lymphocyte count ≤ 3.68 × 10^9/L, and a platelet count ≤ 387 × 10^9/L had a greater effect on PFS in the BLNK-negative group. An age ≥9 years, St. Jude Stages III–IV, the absence of a giant tumor lesion, a chemotherapy regimen (2), a CRP concentration >10.2 mg/L, a B lymphocyte count >18.5 × 10^6/L, an IgG concentration >6.91 g/L, a neutrophil count ≤ 5.6 × 10^9/L, a lymphocyte count >0.49 × 10^9/L, a platelet count >298.5 × 10^9/L, a PLR >199.31, and an NLR >3.17 had a greater effect on OS in the BLNK-negative group. Decreased BLNK expression predicts prolonged PFS among patients with cHL. The validated nomogram integrating BLNK and clinical parameters provides potential predictive value for PFS of cHL. No Clinical trial registration